Comments
Loading...
Ultragenyx Pharmaceutical Earnings Estimates, EPS & Revenue | NASDAQ:RARE | Benzinga
Ultragenyx Pharmaceutical reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 13
EPS
$-1.390
Quarterly Revenue
$164.88M
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$560.23M
Analyze the earnings history of Ultragenyx Pharmaceutical using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical | -$2.03 | — | — | — | $108.83M | — | — | — | 05/01/2025 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.52 | -$1.27 | -$1.39 | -9.45% | $127.39M | $158.71M | $164.88M | 3.89% | 02/13/2025 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.23 | -$1.45 | -$1.40 | 3.45% | $98.05M | $135.79M | $139.49M | 2.73% | 11/05/2024 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.25 | -$1.72 | -$1.52 | 11.63% | $108.31M | $123.18M | $147.03M | 19.36% | 08/01/2024 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.33 | -$1.76 | -$2.03 | -15.34% | $100.50M | $116.17M | $108.83M | -6.32% | 05/02/2024 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.16 | -$1.62 | -$1.52 | 6.17% | $103.35M | $119.38M | $127.39M | 6.71% | 02/15/2024 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.43 | -$2.06 | -$2.23 | -8.25% | $90.70M | $110.02M | $98.05M | -10.88% | 11/02/2023 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.26 | -$2.11 | -$2.25 | -6.64% | $89.34M | $105.20M | $108.31M | 2.96% | 08/03/2023 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.19 | -$1.98 | -$2.33 | -17.68% | $79.94M | $104.69M | $100.50M | -4.01% | 05/04/2023 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.79 | -$2.14 | -$2.16 | -0.93% | $83.39M | $105.12M | $103.35M | -1.69% | 02/16/2023 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.08 | -$1.81 | -$2.43 | -34.25% | $81.65M | $96.20M | $90.70M | -5.71% | 11/02/2022 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.81 | -$1.75 | -$2.26 | -29.14% | $86.97M | $87.51M | $89.34M | 2.09% | 07/28/2022 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.03 | -$1.76 | -$2.19 | -24.43% | $99.39M | $83.65M | $79.94M | -4.44% | 05/05/2022 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$0.37 | -$1.34 | -$1.79 | -33.58% | $91.54M | $83.79M | $83.39M | -0.48% | 02/10/2022 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.13 | -$1.41 | -$1.08 | 23.40% | $81.47M | $81.55M | $81.65M | 0.12% | 11/02/2021 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.12 | -$1.36 | -$1.81 | -33.09% | $61.71M | $85.03M | $86.97M | 2.29% | 08/02/2021 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$2.05 | -$1.24 | -$2.03 | -63.71% | $36.31M | $77.04M | $99.39M | 29.02% | 05/04/2021 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.62 | -$1.16 | -$0.37 | 68.10% | $35.59M | $70.54M | $91.54M | 29.77% | 02/11/2021 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.96 | -$1.27 | -$1.13 | 11.02% | $25.80M | $53.89M | $81.47M | 51.18% | 10/27/2020 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.72 | -$1.54 | -$1.12 | 27.27% | $24.15M | $39.12M | $61.71M | 57.74% | 07/30/2020 | Get Alert |
| RARE | Ultragenyx Pharmaceutical | -$1.82 | -$1.69 | -$2.05 | -21.30% | $18.17M | $36.58M | $36.31M | -0.74% | 05/06/2020 | Get Alert |
Ultragenyx Pharmaceutical (RARE) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-13 | $-1.39 | $-1.27 | -9.45 % |
| Q3 | 2024-11-05 | $-1.40 | $-1.45 | 3.45 % |
| Q2 | 2024-08-01 | $-1.52 | $-1.72 | 11.6 % |
| Q1 | 2024-05-02 | $-2.03 | $-1.76 | -15.3 % |
Ultragenyx Pharmaceutical (RARE) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-13 | $164.88M | $158.71M | 3.89 % |
| Q3 | 2024-11-05 | $139.49M | $135.79M | 2.73 % |
| Q2 | 2024-08-01 | $147.03M | $123.18M | 19.4 % |
| Q1 | 2024-05-02 | $108.83M | $116.17M | -6.32 % |
FAQ
When is Ultragenyx Pharmaceutical (NASDAQ:RARE) reporting earnings?
Ultragenyx Pharmaceutical (RARE) is scheduled to report earnings on May 1, 2025. The last reported earnings were for reported on February 13, 2025 for Q4.
What were the latest earnings per share (EPS) for Ultragenyx Pharmaceutical (NASDAQ:RARE)?
The Actual EPS was $-1.39, which missed the estimate of $-1.27.
What were Ultragenyx Pharmaceutical’s (NASDAQ:RARE) revenues?
The Actual Revenue was $164.9M, which beat the estimate of $158.7M.
Browse earnings estimates, EPS, and revenue on all stocks.